Molecular Pathology Laboratory Network

A retrospective study conducted by Sloan-Kettering Cancer Center showed that KRAS mutation and Ki-67 expression correlate with accelerated metastatic progression in patients with colorectal liver metastases.

In a patient study population of 188, 27% were found to have a KRAS mutation, while high Ki-67 expression was demonstrated in 62% of patients. The two markers were independent predictors of poor survival after initial colon surgery, and both were associated with presence of multiple liver metastases as well as a shorter time to detection from initial diagnosis.

Patients with tumors that had both KRAS mutation and high expression of Ki-67 experienced worse disease-specific survival compared to patients with KRAS mutation and low levels of Ki-67. In addition, the presence of a KRAS mutation correlated with poorer survival compared with KRAS wild type after successful resection of both the primary and metastatic tumors.

For more information about the KRAS mutation test or Ki-67, contact one of our client service specialists at 800.932.2943.